Abstract We investigate the effects mediated by glucocorticoid (GC) receptor (GR) blockage by using RU486, a GR antagonist and GR short interfering RNA (GR siRNA) on the proliferative and differentiation capabilities of human bone marrow mesenchymal stromal/stem cells (MSCs) and on their senescence and antioxidant levels during extended in vitro culture. Treatment with either RU486 or GR siRNA for a 7-day period significantly increased the proliferation of MSCs and their osteogenic capabilities, as reflected by an increase in alkaline phosphatase (ALP) levels after differentiation. Following 4 weeks of treatment, MSCs improved or maintained their proliferation rates, whereas control MSCs exhibited decreased proliferation. Although all MSCs exhibited reduced osteogenic potential after 4 weeks of in vitro culture, the MSCs treated with GR inhibitors showed higher ALP levels than untreated MSCs on being subjected to osteogenic differentiation. Such treatment also significantly down-regulated the adipogenic capabilities of MSCs. Telomere lengths and the activities of telomerase and superoxide dismutase of MSCs treated with either RU486 or GR siRNA appeared to be higher than those detected in controls. These results demonstrate that the blockage of effects mediated by the GCs normally found in fetal bovine serum might postpone senescence of these cells by up-regulating their antioxidant levels. Our data suggest that the blocking of the effects mediated by GCs might extend the lifespan of endogenous MSCs in patients who have elevated GC levels as a consequence of advancing age or estrogen depletion.
Introduction
Bone marrow mesenchymal stem/stromal cells (MSCs) are capable of differentiating into many cell types and can replace these cells when they are lost or damaged (Dennis and Caplan 1993; Petersen et al. 1999) . Imbalances in steroid hormone levels and aging have been demonstrated to induce senescence of these stem cells, resulting in both decreased proliferation and osteochondrogenic differentiation and increased adipocyte differentiation (Rodriguez et al. 1999; Ray et al. 2008; D'Ippolito et al. 1999) . Such alterations in bone marrow MSCs can ultimately contribute to the development of osteoporosis and osteoarthritis, because these stem cells have lost their potential to contribute to bone and cartilage formation (Manolagas 2010; Kretlow et al. 2008; Erickson et al. 2011 ). In addition, because of their high ex vivo proliferative capabilities and strong osteochondrogenic differentiation potential, bone marrow MSCs have also been considered a potential cell source for the tissue engineering of bone and cartilage (Pittenger et al. 1999; Barry and Murphy 2004) . Unfortunately, in vitro expansion of these cells by using current culture techniques induces senescence that abruptly reduces their proliferative and osteochondrogenic capabilities and seriously limits their potential usefulness in osteochondral regeneration (Vacanti et al. 2005; Baksh et al. 2004; Kolf et al. 2007 ). Therefore, a more thorough understanding of steroid-mediated regulation of MSC characteristics is required in order to develop protocols that might postpone their senescence. This new information is essential in order to develop an appropriate treatment to improve MSC capabilities in terms of osteochondral regeneration and to develop an effective approach for the prevention of MSC senescence-associated osteoporosis.
Glucocorticoids (GCs) play a major role in regulating the proliferation and differentiation of MSCs via classic glucocorticoid receptors (GR), classified as type 2 receptor for GCs (Chen 2004; Dennis and Caplan 1996) . Elevated endogenous levels of GCs potentially reduce proliferation and induce apoptosis in many cell types, including osteoblasts and osteocytes (Kim et al. 1999) . In addition, the effects mediated by GCs might accelerate cell aging and shorten telomere length by increasing oxidative stress and downregulating the activity of telomerase and antioxidant levels (Ichiyoshi et al. 2003; Wen et al. 2002; Costantini et al. 2011; Brandl et al. 2011) . Elevated levels of endogenous GCs also contribute to MSC senescence and the development of osteoporosis in aging patients and in those who are postmenopausal and hence estrogen-depleted (Baksh et al. 2004; Kolf et al. 2007; Chen 2004; Dennis and Caplan 1996; Kim et al. 1999; Ichiyoshi et al. 2003; Wen et al. 2002; Costantini et al. 2011; Brandl et al. 2011; Kizaki et al. 2000; Nakamura and Yakata 1984; Nicolson et al. 1997; Woods et al. 2009 ). Our previously published data have shown that short-term blockage of the effects mediated by the GCs present in fetal bovine serum (FBS) by using either the GR antagonist RU486 or the small interfering RNA (siRNA) for GR significantly improves the proliferative and osteochondral differentiation capabilities of human MSCs Hong et al. 2012) . However, because of the short-term nature of these previously conducted experiments, we were unable to assess the potential effectiveness of both of these treatments on the senescence and antioxidant activity of these stem cells. In order to address this major limitation, our goal in the present long-term study has been to investigate the in vitro effects of both of these GR inhibitors not only on the capabilities of MSCs, including proliferation and differentiation but also on their senescence. The data presented in this report demonstrate that blockage of the effects mediated by the GCs normally found in FBS during a long-term in vitro expansion effectively maintains the proliferative capabilities of MSCs and postpones the reduction in their osteogenic capabilities.
Our new results clearly demonstrate that both of these two independent approaches for blocking GR-mediated responses increase the expression of telomerase and telomere length and superoxide dismutase (SOD) activity. Taken collectively, these data strongly suggest that, by blocking the effects mediated by GCs, we might be able to develop a protocol that will improve MSC proliferation and osteochondral differentiation and postpone the onset of senescence in these human stem cells.
Materials and methods

Preparation of human MSCs
Fresh human bone marrow, donated by a total of six healthy male and female donors from 22 to 43 years of age, were purchased from Allcells (Emeryville, Calif., USA). Mononuclear cells were isolated by using density gradient centrifugation (Histopaque-1.077; Sigma, St. Louis, Mo., USA) and subsequently cultured in Dulbecco's modified Eagle's Medium (DMEM; Invitrogen, Carlsbad, Calif., USA) supplemented with 10 % FBS (Atlanta Biologicals, Lawrenceville, Ga., USA) and 1 % antibioticantimycotic (Sigma). At 5 days after plating, non-adherent cells were removed during medium exchange. The adherent cells continued to proliferate and were collected when they reached 70-80 % confluence. The cells were then cultured in 100-mm Petri dishes (passage-1) with an initial seeding density of 10 5 cells/dish. Passage-1 cells were subsequently used to test the effects of the blockage of GC-mediated responses on the proliferation and differentiation of MSCs.
Treatment with RU486 and GR siRNA Both cortisol (average 7 μg/100 ml) and corticosterone (approximately 3.0 μg/100 ml) have been shown to be major glucocorticoids in bovine plasma (Venkataseshu and Estergreen 1970) . These published data for adult bovine serum are consistent with the corticosterone levels (2.4 μg/100 ml) that we have directly measured in FBS. Our previously published data have demonstrated that 10 -8 M of the GR antagonist RU486 effectively blocks the effects mediated by these GCs normally found in FBS . We therfore used RU486 at a final concentration of 10 -8 M in the present experiments. Untreated MSCs served as controls.
GR-siRNA-loaded poly(lactic-co-glycolic acid) (PLGA) particles were prepared by using a (water-in-oil)-in-water double emulsion solvent evaporation method as previously described . Briefly, GR siRNA (50 μg) was added to 300 μl of a 1 % aqueous solution of polyvinyl alcohol (PVA; water 1 phase). The water 1 phase was emulsified into the oil phase, which was prepared by dissolving 6.67 % w/v PLGA polymer in 2 ml dichloromethane (DCM). This primary water-in-oil emulsion was then immediately sonicated into 4 ml aqueous phase containing 1 % PVA for 30 s to generate the secondary emulsion. The secondary emulsion was then dropped slowly into a beaker containing 25 ml of 1 % aqueous solution of PVA and stirring was continued by using a magnetic stirrer until complete evaporation of DCM. The particles were collected by centrifugation at 5000 g for 5 min, washed three times with distilled water and lyophilized overnight. For treatment with GR siRNA, 1 mg GR-siRNA-loaded particles containing 0.12 μg GR siRNA was suspended in DMEM and added to human MSCs cultured on a 100-mm Petri dish for 24 h. The MSCs were then washed twice with phosphate-buffered saline (PBS) to remove suspended particles. Our previous study had shown that the GR-siRNA-loaded PLGA particles at this concentration effectively down-regulated GR mRNA expression in MSCs . The GR mRNA level down-regulated by the siRNA treatment returned to near control levels (minus siRNA) after 5 days (Woods et al. 2009 ). Thus, in our study, the siRNA-loaded particles at this dose were added to MSCs weekly during in vitro culture.
After 1 and 4 weeks, MSCs in the various treatment groups were collected and analyzed for their GR (NR3C1) level, proliferation rate, multiple differentiation potentials, telomerase expression, telomere length and SOD activity.
GR level and proliferation capabilities of MSCs
After being pretreated for 1 or 4 weeks with RU486 or GR siRNA, human MSCs were collected and cultured in 96-well (1000 cells/well) plates with steroid-free medium consisting of phenol-red-free DMEM supplemented with 1 % charcoalstripped FBS. MSC DNA content was measured by using a DNA quantification kit (FluoReporter Blue Fluorometric dsDNA Quantitation Kit, Invitrogen) according to the manufacturer's protocol. The difference in DNA content after every 48 h was used to determine the MSC proliferation rate as described in our previous studies Hong et al. 2012) . The NR3C1 levels after the various treatments were measured by using a commercially available enzymelinked immunosorobent assay (MyBioSource, San Diego, Calif., USA).
Differentiation capacities of human MSCs
In order to measure the differentiation capabilities of human MSCs, the cells were washed twice with PBS and trypsinized after 1 or 4 weeks of treatment with RU486 or GR siRNA. The cells were subsequently cultured in 6-well plates (10 4 cells/well) and exposed to osteogenic or adipogenic differentiation medium for up to 3 weeks. The differentiation medium for osteogenesis consisted of the basic medium supplemented with 100 nM dexamethasone, 10 mM β-glycerophosphate and 0.05 mM ascorbic acid-2-phosphate. The osteocalcin (OCN) expression, alkaline phosphatase (ALP) and calcium content of MSCs following osteogenic differentiation were measured in triplicate as described in our previous studies (Hong et al. 2006) . For adipogenesis, the medium was supplemented with 50 nM dexamethasone, 10 μM insulin and 0.5 mM isobutyl-methylxanthine. We used real-time polymerase chain reaction (PCR) to quantify the expression of peroxisome proliferator-activated receptors (PPAR)-γ2 and lipoprotein lipase (LPL), which are both adipogenic differentiation markers for MSCs. The real-time PCR primers and probes for multiple differentiation markers were described in our previous study ).
Effects of GC blockages on telomere length, telomerase expression and SOD activity After 4 weeks of RU486 or GR siRNA treatment, the SOD activity of MSCs was evaluated by measuring the dismutation of superoxide radicals generated by xanthine oxidase and hypoxanthine with a commercial kit according to the manufacturer's protocol (Cayman Chemical). The mRNA expression of telomerase was measured by using real-time PCR. The Syber Green Real-time PCR primers and probe were: forward 5'-GGA GAA CAA GCT GTT TGC GG-3' and reverse 5'-AGG TTT TCG CGT GGG TGA G-3' (ABI, Calif., USA). The primers for D-glyceraldehyde-3-phosphate dehydrogenase were purchased from Applied Biosystems. We also measured the average telomere length from total genomic DNA by using a real-time PCR method (Gil and Coetzer 2004) . This assay measures an average telomere length ratio (ATLR) by quantifying telomeric DNA with specially designed primer sequences and dividing that amount by the quantity of a single-copy gene. Briefly, genomic DNA was extracted by using the Qiagen DNA kit. The forward and reverse primers for telomere were GGC TTT TAT GGG TAT GGG TAT GGG TAT GGG TAT GGG TT and TCC CGA CTT ACC CTT ACC CTT ACC CTT ACC CTT ACC CT, respectively. The 36B4 (encodes acidic ribosomal phosphoprotein PO) forward and reverse primers were TCG TCT TTA AAC CCT GCG TG and TGT CTG CTC CCA CAA TGA AAC, respectively. An individual sample of rat DNA was serially diluted over a 12-fold range of telomere concentrations to generate standard curves. Input amounts were calculated for each sample by using the same protocol. The relative input amount of the telomere PCR was divided by the relative input amount of the 36B4 PCR of the same sample. Real-time PCR was repeated a minimum of three times for every sample and the ratio of telomere:36B4 was calculated. The average of these ratios was reported as the ATLR.
Statistics
All quantitative data were expressed as means ± SD and descriptive statistics were conducted by using SAS for Windows (v9.3, SAS Institute, Cary, N.C., USA). The nonparametric Wilcoxon signed-rank test was used to detect the significant differences in proliferation rates, differentiation and premature senescence of MSCs receiving the various treatments. A P-value of less than 0.05 was used as a criterion for statistical significance and 0.05<P <0.10 was used as a criterion for marginal significance.
Results
GR variations and MSC proliferative capabilities following in vitro treatment with RU486 or GR siRNA Figure 1 shows the GR level and proliferative capabilities of human bone marrow MSCs after being pretreated with RU486 or GR siRNA. Following a 1-week treatment with either GR siRNA or RU486, MSCs showed significantly higher proliferation rates than those of control MSCs. Whereas the proliferation rate of control cells appeared to decrease after 4 weeks of in vitro culture, the MSCs treated with either RU486 or GR siRNA maintained high proliferation rates. The proliferation rates of MSCs 4 weeks after being treated so as to block endogenous GCs were significantly higher than those of controls (Fig. 1a) . Our previous studies had demonstrated that treatment with GR siRNA-loaded PLGA particles knocked down the expression of GR mRNA in MSCs and that the GR mRNA level returned to near control levels after 5 to 7 days . No significant difference of GR mRNA expression was observed in the MSCs treated with RU486 or GR siRNA compared with controls after 4 weeks when MSCs started to differentiate (Fig. 1b) . The protein levels of NR3C1 in MSCs treated with GR siRNA were down-regulated at day 7. However, the GR levels were returned to near control levels at day 14 (Fig. 1c) .
Differentiation capabilities of human MSCs following in vitro treatment with RU486 or GR siRNA
In MSCs treated with RU486 or GR siRNA for 1 week and then exposed to osteogenic differentiation medium for 3 weeks, mineral deposition, as indicated by blackness after von-Kossa staining, was detected in control MSCs (Fig. 2d ) and MSCs pretreated with RU486 (Fig. 2e) or GR siRNA (Fig. 2f) . Staining in MSCs that had been pretreated with GR siRNA (Fig. 2f ) appeared darker than that detected in controls (Fig. 2d) . In MSCs pretreated with RU486 or GR siRNA for 4 weeks, although the mineral deposition became slightly less intense in most MSCs (treated and untreated) after osteogenic differentiation for 3 weeks, MSCs that had been pretreated with RU486 appeared to stain darker than controls (Fig. 2j-l) . Quantitatively, after MSCs had been exposed to osteogenic differentiation medium for 2 weeks, ALP levels in the MSCs that had been pretreated with GR siRNA or RU 486 for 1 week were significantly higher than the levels detected in controls. The ALP levels decreased in all MSCs after 4 weeks in vitro culture with the various treatments. However, the ALP level in MSCs pretreated for 4 weeks with GR siRNA or RU486 appeared to be higher than the level detected in controls (Fig. 3a) . Similarly, the gene expression of OCN in the MSCs that had been pretreated with GR siRNA or RU 486 for 1 week were slightly higher than the level detected in controls. The OCN levels decreased in control MSCs after 4 weeks in vitro culture. However, the OCN level in MSCs pretreated for 4 weeks with GR siRNA or RU486 appeared to be higher than the level detected in controls (Fig. 3b) . The calcium content in five out of six plates of human MSCs pretreated Fig. 1 Glucocorticoid receptor (GR) characterization and proliferation capabilities of human mesenchymal stem cells (MSCs) after the various treatments. a Percentage difference in DNA content (measured every 48 h) in MSCs after 1 and 4 weeks (w) of pretreatment with GR short interfering RNA (GR siRNA) or RU486 in vitro. n =6, means ± SD; *P <0.05, **P <0.01. b GR mRNA expression in MSCs treated with RU486 or GR siRNA after 4 weeks. c Protein levels of NR3C1 in MSCs treated with GR siRNA or RU486 at various time points. All samples were measured in triplicate with GR siRNA for 1 week was also higher than that of controls after these cells had been exposed to osteogenic differentiation medium. The calcium content in four out of six plates of MSCs pretreated with RU486 for 4 weeks appeared higher than that of controls (Fig. 3c) , although no statistical difference was observed between these two groups because of limited sample size.
After exposure to adipogenic differentiation medium, lipid accumulations, as detected by Oil-red-O staining, were observed in all groups of MSCs pretreated for 1 week (Fig. 4a-c) . No detectable decrease in lipid accumulation appeared in MSCs receiving the various pretreatments for 4 weeks (Fig. 4d-f) . However, the expression of mRNA for adipogenic markers after differentiation, including PPAR (Fig. 5a ) and LPL (Fig. 5b) , were lower in MSCs pretreated with RU486 or GR siRNA for 1 week. All MSCs after 4 weeks of in vitro culture exhibited decreased expression of both adipogenic markers and the treatment with GR siRNA or RU486 for 4 weeks further decreased PPAR or LPL expression (Fig. 5a, b) . Fig. 2 Images of von-Kossastained MSCs receiving the various treatments and after in vitro osteogenic differentiation. MSCs pretreated with controls (a, d, g, j) , RU486 (b, e, h, k) and GR siRNA (c, f, i, l) for 1 (a-f) and 4 (g-l) weeks after exposure to nondifferentiation medium (a-c, g-i) and osteogenic differentiation medium (d-f, j-l) Telomerase expression, telomere length and SOD activity in MSCs treated with RU486 or GR siRNA Figure 6 shows the quantitation of telomerase expression, telomere length and SOD activity in MSCs treated with GR siRNA or RU486 for 4 weeks. Treatment with RU486 or GR siRNA significantly up-regulated the expression of telomerase mRNA (Fig. 6a) . The telomere lengths of MSCs treated with RU486 were significantly longer than those in controls (Fig. 6b) . The MSCs treated with GR siRNA also had relatively longer telomeres than those in controls but the differences were only marginally significant (P =0.0625). In addition, the total activity of SOD, which is a key antioxidant, was 30-40 % higher in MSCs that had been treated with RU486 or GR siRNA than in controls; these differences were statistically significant (Fig. 6c) .
Discussion
Our previous studies have revealed that GCs can inhibit MSC proliferation and down-regulate the expression of fibroblast growth factor-2 (FGF-2), which is a "stemness" gene that potentially up-regulates antioxidant levels and prevents the senescence of MSCs ). The GC responses in MSCs are mediated via type 2 intracellular GR and hence, blockage of the effects mediated by GCs contained in culture medium by using GR siRNA or RU486 has been shown to improve the capability of MSCs for proliferation and to increase the expression of osteogenic differentiation markers Hong et al. 2012 ). The present study further demonstrates that both of these distinct treatments up-regulate the expression of telomerase mRNA, increase antioxidant levels and increase MSC telomere length during in vitro expansion. These anti-senescence responses might explain the mechanism underlying the improvement mediated by both of these treatments on the proliferative and osteogenic capabilities of MSCs during in vitro culture. The progression of MSC senescence in vitro has been demonstrated to resemble that which occurs in vivo during human aging (Wagner et al. 2009 ). The results presented here indicate that the blockage of the effects mediated by endogenous GCs might be further developed as a protocol for effectively preventing or delaying the senescence of MSCs and extending their lifespan in human patients. Fig. 3 Osteogenic capabilities of MSCs that had received the various treatments. a Alkaline phosphatase (ALP) activity in MSCs after various pretreatments for 1 and 4 weeks and following osteogenic differentiation in vitro for 2 weeks. b Calcium content (Ca++) in MSCs after various pretreatments for 1 and 4 weeks and following osteogenic differentiation in vitro for 3 weeks. n =6; means ± SD; *P <0.05. c mRNA expression of osteocalcin (OCN) in MSCs pretreated with GR siRNA or RU 486 for 1 and 4 weeks followed by osteogenic differentiated for 2 weeks. All samples were measured in triplicate Because of their high proliferative capabilities, MSCs expanded in vitro have been used for potential osteochondral regeneration. However, recent studies demonstrate that, when cultured in vitro, these cells exhibit the characteristics of senescence, as evidenced by their reduced proliferation and their loss of osteogenic differentiation (Barry and Murphy 2004; Vacanti et al. 2005; Baksh et al. 2004; Kolf et al. 2007 ). In the present study, we have also observed the reduction in the proliferative capabilities of MSCs and in the osteogenic differentiation capabilities of these cells as reflected by ALP activity, OCN expression and calcium content after 4 weeks of in vitro expansion. Although the exact mechanism(s) underlying the senescence of MSCs in vitro is not clear, increased oxidative stress levels and the reduced activity of antioxidants have been observed after in vitro culture (Ebert et al. 2006; Ho et al. 2011; Kasper et al. 2009 ). Enhanced oxidative stress has been demonstrated to induce senescence of these cells both in vitro and in vivo (Brandl et al. 2011; Kasper et al. 2009 ). Supplementation with exogenous antioxidants has also been shown to increase the potential for MSC proliferation and osteogenic differentiation (Ebert et al. 2006) . GCs have been demonstrated to in MSCs that received the various pretreatments in vitro for 1 and 4 weeks and after they were exposed to adipogenic differentiation medium for 2 weeks. n =6; means ± SD. *P <0.05 increase oxidative stress and to reduce levels of antioxidants (Ebert et al. 2006) . In this study, we have observed, for the first time, that an increase occurs in SOD activity following the in vitro treatment of MSCs with either GR siRNA or RU486. In addition, the expression of telomerase mRNA and telomere length, both of which are markers for cell aging, are increased following the treatment of MSCs with GR siRNA or RU486. These data strongly suggest that the blockage of the effects mediated by the GCs found in the FBS contained in complete culture medium might improve the antioxidant capabilities of MSCs and prevent or postpone the onset of senescence in these cells. We have further observed that MSCs treated with GR siRNA or RU486 exhibit increased proliferation rates when compared with those of controls. The ALP levels detected in MSCs undergoing osteogenic differentiation have also been found to be significantly increased compared with those of controls. Since bone-specific ALP levels of differentiated MSCs in vitro correlate with their in vivo bone regenerative capabilities (Mendes et al. 2004) , the enhancement of ALP in treated MSCs suggests that these cells have higher bone regeneration potentials. These enhancements in the proliferation and osteogenic potential of MSCs treated with GR siRNA or RU486 further support the hypothesis that the blockage of GC-mediated responses can potentially prevent the senescence of MSCs.
The senescence of MSCs, which can be enhanced by elevated GC levels during aging and in postmenopausal patients, has been demonstrated to lead to the increased adipogenic differentiation of these cells. These responses might contribute to the development of osteoporosis and obesity in these patients. Although, in the current study, telomere length and telomerase expression levels have been shown to be increased in MSCs pretreated with RU486 or GR siRNA, we have not observed any significant differences in lipid accumulation. Furthermore, in the present study, we have observed that the expression of mRNA for adipogenic differentiation markers, including PPAR-γ and LPL, is decreased in all MSCs after 4 weeks of in vitro culture. Pretreatment with GR siRNA or RU486 also down-regulates the expressions of PPARγ and RU486. Although the underlying mechanism(s) are not clear, one possibility is that the extent of MSC senescence after 4 weeks of the various treatments might not have been sufficient to cause an increase in adipogenic differentiation, similar to that occurring during aging and in postmenopausal patients. In addition, a previous study has demonstrated that MSCs can maintain adipogenic differentiation after extended culture in vitro, although they might lose their proliferative properties and osteochondral differentiation capabilities after long-term in vitro culture (Vacanti et al. 2005) . These data suggest that in vitro senescence has less of an effect on the adipogenic differentiation of MSCs and/or that the adipogenic differentiation of MSCs in vitro might have different underlying mechanism(s) from the mechanisms underlying this process when it occurs in patients with advanced age or after the menopause.
Steroid hormones have been demonstrated to regulate oxidative stress and the levels of antioxidants in many tissue and cell types. Physiologically, estrogens function as antioxidants and promote MSC proliferation and osteogenic differentiation (White et al. 2010; Baltgalvis et al. 2010) . In contrast, GCs inhibit MSC proliferation, accelerate senescence and increase oxidative stress (Chen 2004; Costantini et al. 2011) . GCs have been demonstrated to play a critical role in bone metabolism by actively regulating proliferation, differentiation and senescence of bone marrow MSCs (Dennis and Caplan 1996; Kim et al. 1999; Ichiyoshi et al. 2003) . Thus, patients with advancing age and those who are postmenopausal, i.e., characterized as having decreased estrogen levels and features mediated by elevated endogenous GC levels, have increased oxidative stress and reduced antioxidant activity (Brandl et al. 2011; Kizaki et al. 2000; Nakamura and Yakata 1984; Nicolson et al. 1997; Woods et al. 2009 ). These factors appear to induce the senescence of MSCs, an event that eventually serves to trigger steroid-or age-related osteoporosis, which is characterized by decreased bone regeneration. Therefore, by effectively regulating or blocking these GC-mediated responses, we might be able to reduce oxidative stress and increase the levels of antioxidants, thereby preventing or delaying the senescence of MSCs and rejuvenating their physiological capabilities. This approach, if accomplished via a delivery system that specifically targets bone marrow MSCs, could be potentially beneficial in patients with GC-induced osteoporosis, because it might improve the regenerative capabilities of MSCs by suppressing or postponing the onset of their senescence.
